Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health and the University of Pennsylvania to settle royalty claims related to sales of its COVID-19 vaccine ...

“BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter BioNTech SE has reached a settlement agreement with the University ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer.

Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a biotechnology company primarily focused on developing and manufacturing ...